Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 274-286 , July 2008

Single-Photon Emission Computed Tomography and Positron Emission Tomography Evaluations of Patients With Central Motor Disorders

  • John P. Seibyl, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to John P. Seibyl, MD, Institute for Neurodegenerative Disorders, Molecular Neuroimaging, LLC, Yale University School of Medicine, 60 Temple Street, 8B, New Haven, CT 06510.

References 

  1. Becker G, Muller A, Braune S, et al. Early diagnosis of Parkinson's disease. J Neurol. 2002;249(suppl 3):III40–III48
  2. Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: Development of optimal discrimination criteria. Neurodegeneration. 1995;4:93–97
  3. Sonies BC. Patterns of care for dysphagic patients with degenerative neurological diseases. Semin Speech Lang. 2000;21:333–344quiz 334-335
  4. Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord. 2005;20(suppl 11):S23–S29
  5. Goetz CG, Vogel C, Tanner CM, et al. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology. 1998;51:811–814
  6. Albanese A, Colosimo C, Bentivoglio AR, et al. Multiple system atrophy presenting as parkinsonism: Clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry. 1995;59:144–151
  7. Bergareche A, De La Puente E, Lopez de Munain A, et al. Prevalence of Parkinson's disease and other types of Parkinsonism (A door-to-door survey in Bidasoa, Spain). J Neurol. 2004;251:340–345
  8. Duvoisin RC, Golbe LI, Lepore FE. Progressive supranuclear palsy. Can J Neurol Sci. 1987;14(suppl 3):547–554
  9. Geldmacher DS. Differential diagnosis of dementia syndromes. Clin Geriatr Med. 2004;20:27–43
  10. Jankovic J, Rajput AH, McDermott MP, et al. The evolution of diagnosis in early Parkinson disease (Parkinson Study Group). Arch Neurol. 2000;57:369–372
  11. Adler CH. Differential diagnosis of Parkinson's disease. Med Clin North Am. 1999;83:349–367
  12. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–39
  13. Breit S, Schulz JB, Benabid AL. Deep brain stimulation. Cell Tissue Res. 2004;318:275–288
  14. Brundin P, Pogarell O, Hagell P, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 2000;123:1380–1390
  15. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin InvestDrugs. 2003;12:1335–5132
  16. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Invest Drugs. 2004;5:720–726
  17. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–1053
  18. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?. Mov Disord. 2003;18(suppl 7):S63–S70
  19. Ohtake H, Limprasert P, Fan Y, et al. Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology. 2004;63:805–811
  20. Karlsson P, Farde L, Halldin C, et al. PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl). 1993;113:149–156
  21. Burghaus L, Schutz U, Krempel U, et al. Loss of nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat Disord. 2003;9:243–246
  22. Parain K, Hapdey C, Rousselet E, et al. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res. 2003;984:224–232
  23. Brooks DJ. PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol. 1997;6:69–87
  24. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol. 2001;86:237–247
  25. Brucke T, Djamshidian S, Bencsits G, et al. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol. 2000;247(suppl 4):IV/2-7
  26. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589–598
  27. Marek KL, Seibyl JP, Zoghbi SS, et al. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology. 1996;46:231–237
  28. Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med. 1997;38:1–6
  29. Antonini A, DeNotaris R. PET and SPECT functional imaging in Parkinson's disease. Sleep Med. 2004;5:201–206
  30. Au WL, Adams JR, Troiano AR, et al. Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. Brain Res Mol Brain Res. 2005;134:24–33
  31. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol. 2003;184(suppl 1):S68–S79
  32. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–319
  33. Winogrodzka A, Bergmans P, Booij J, et al. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm. 2001;108:1011–1019
  34. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64:208–215
  35. Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879–1884
  36. Covelli EM, Brunetti A, Di Lauro A, et al. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease. Radiol Med (Torino). 2004;108:417–425
  37. Marshall V, Grosse D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18:1415–1423
  38. Rinne OJ, Nurmi E, Ruottinen HM, et al. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse. 2001;40:193–200
  39. Tissingh G, Bergmans P, Winogrodzka A, et al. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1997;38:1271–1272
  40. Chou KL, Hurtig HI, Stern MB, et al. Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease. Parkinsonism Relat Disord. 2004;10:375–379
  41. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40:873–884
  42. Geng Y, Shi GH, Jiang Y, et al. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease. J Zhejiang Univ Sci B. 2005;6(1):22–27
  43. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med. 1997;38:1453–1459
  44. Rusjan P, Mamo D, Ginovart N, et al. An automated method for the extraction of regional data from PET images. Psychiatry Res. 2006;147:79–89
  45. Chan GL, Holden JE, Stoessl AJ, et al. Reproducibility studies with 11C-DTBZ, a monoamine vesicular transporter inhibitor in healthy human subjects. J Nucl Med. 1999;40:283–289
  46. Hwang WJ, Yao WJ, Wey SP, et al. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med. 2004;45:207–213
  47. Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab. 2000;20:1604–1609
  48. Tsuchida T, Ballinger JR, Vines D, et al. Reproducibility of dopamine transporter density measured with 123I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med. 2004;18:609–616
  49. Zubal IG, Early M, Yuan O, et al. Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients. J Nucl Med. 2007;48:857–864
  50. Laruelle M, Wallace E, Seibyl JP, et al. Graphical, kinetic, equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994;14:982–994
  51. Seibyl J, Jennings D, Tabamo R, et al. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva Med. 2005;96:353–364
  52. Booij J, Speelman JD, Horstink MW, et al. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–272
  53. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol. 1998;44(suppl 1):S10–S18
  54. Emami-Avedon SS, Ichise M, Lang AE. The use of SPECT in the diagnosis of Parkinson's disease. Can Assoc Radiol J. 2000;51:189–196
  55. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing. 1999;28:99–102
  56. Quinn N. Parkinsonism—recognition and differential diagnosis. BMJ. 1995;310:447–452
  57. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181–184
  58. Rajput DR. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1993;56(8):938–939
  59. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287:1653–1661
  60. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003;54:93–101
  61. Gerlach M, Double K, Reichmann H, et al. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. J Neural Transm Suppl. 2003;65:167–183
  62. Kostrzewa RM, Kostrzewa JP, Brus R. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease. Amino Acids. 2002;23:57–63
  63. Fernandez HH, Friedman JH, Fischman AJ, et al. Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?. Med Sci Monit. 2001;7:1339–1343
  64. Huang WS, Lee MS, Lin JC, et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2004;31:155–161
  65. Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging. 2002;29:1623–1629
  66. Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord. 2003;18(suppl 7):S16–S21
  67. Weng YH, Yen TC, Chen MC, et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med. 2004;45:393–401
  68. Jennings DL, Seibyl JP, Oakes D, et al. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: Unmasking an early diagnosis. Arch Neurol. 2004;61:1224–1229
  69. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175–1182
  70. Ceravolo R, Volterrani D, Gambaccini G, et al. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: Evidence from a dopamine transporter imaging study. J Neural Transm. 2004;111:1065–1073
  71. Walker Z, Costa DC, Walker RW, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62:1568–1572
  72. Litvan I, Maclntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998;55:969–978
  73. Thobois S, Vingerhoets F, Fraix V, et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol. 2004;61:1705–1709
  74. Wenning GK, Donnemiller E, Granata R, et al. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord. 1998;13:438–445
  75. Ichise M, Kim YJ, Ballinger JR, et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology. 1999;52:1206–1214
  76. Kim YJ, Ichise M, Ballinger JR, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, PSP. Mov Disord. 2002;17:303–312
  77. Andrews RJ. Neuroprotection for the new millennium (Matchmaking pharmacology and technology). Ann N Y Acad Sci. 2001;939:114–125
  78. Clarke CE. A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs?. Mov Disord. 2004;19:491–498
  79. Drukarch B, van Muiswinkel FL. Neuroprotection for Parkinson's disease: A new approach for a new millennium. Expert Opin Invest Drugs. 2001;10:1855–1868
  80. Wolters EC, Francot C, Bergmans P, et al. Preclinical (premotor) Parkinson's disease. J Neurol. 2000;24(suppl 2):II103–II109
  81. Tissingh G, Berendse HW, Bergmans P, et al. Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosis. Mov Disord. 2001;16:41–46
  82. Guilloteau D, Chalon S. PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders. Curr Pharm Des. 2005;11:3237–3245
  83. Seibyl J, Jennings D, Tabamo R, et al. Neuroimaging trials of Parkinson's disease progression. J Neurol. 2004;251(suppl 7):vII9–vII13
  84. Vingerhoets FJ, Snow BJ, Lee CS, et al. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol. 1994;36:759–764
  85. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007;69:1480–1490
  86. Laruelle M, D'Souza CD, Baldwin RM, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 1997;17:162–174
  87. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235–9340
  88. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. Neurology. 2006;67:1612–1617
  89. Nakagawa M, Kuwabara Y, Taniwaki T, et al. PET evaluation of the relationship between D2 receptor binding and glucose metabolism in patients with parkinsonism. Ann Nucl Med. 2005;19:267–275
  90. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: Implications for dyskinesias. Brain. 2004;127:2747–2754
  91. Dentresangle C, Veyre L, Le Bars D, et al. Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]raclopride PET study. Mov Disord. 1999;14:1025–1030
  92. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211
  93. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318:121–134
  94. Braak H, Muller CM, Rub U, et al. Pathology associated with sporadic Parkinson's disease—where does it end?. J Neural Transm Suppl. 2006;70:89–97
  95. Di Paola R, Uitti RJ. Early detection of Parkinson's disease (Implications for treatment). Drugs Aging. 1996;9:159–168
  96. Brooks DJ, Piccini P. Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry. 2006;59:908–918
  97. Aarsland D, Karlsen K. Neuropsychiatric aspects of Parkinson's disease. Curr Psychiatry Rep. 1999;1:61–68
  98. Sawabini KA, Watts RL. Treatment of depression in Parkinson's disease. Parkinsonism Relat Disord. 2004;10(suppl 1):S37–S41
  99. Haapaniemi TH, Ahonen A, Torniainen P, et al. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord. 2001;16:124–130
  100. Berding G, Brucke T, Odin P, et al. [123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin. 2003;42:31–38
  101. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol. 2007;14:523–528
  102. Schou M, Sóvágó J, Pike VW, et al. Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram. Mol Imaging Biol. 2006;8:1–8
  103. Tamagnan GD, Brenner E, Alagille D, et al. Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007;17:533–537
  104. Braak H, Rub U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci. 2006;248:255–258
  105. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord. 2007;22:1272–1277
  106. Dujardin K, Defebvre L, Duhamel A, et al. Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol. 2004;251:1383–1392
  107. Elias JW, Treland JE. Executive function in Parkinson's disease and subcortical disorders. Semin Clin Neuropsychiatry. 1999;4:34–40
  108. Green J, McDonald WM, Vitek JL, et al. Cognitive impairments in advanced PD without dementia. Neurology. 2002;59:1320–1324
  109. Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology. 2000;54:1596–1602
  110. Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson's disease. Arch Neurol. 1988;45:260–262
  111. McFadden L, Mohr E, Sampson M, et al. A profile analysis of demented and nondemented Parkinson's disease patients. Adv Neurol. 1996;69:339–341
  112. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol. 1998;44(suppl 1):S1–S9
  113. Press DZ. Parkinson's disease dementia—a first step?. N Engl J Med. 2004;351:2547–2549
  114. Belluardo N, Mudo G, Blum M, et al. Central nicotinic receptors, neurotrophic factors and neuroprotection. Behav Brain Res. 2000;113:21–34
  115. Kelton MC, Kahn HJ, Conrath CL, et al. The effects of nicotine on Parkinson's disease. Brain Cogn. 2000;43:274–282
  116. Mihailescu S, Drucker-Colin R. Nicotine and brain disorders. Acta Pharmacol Sin. 2000;21:97–104
  117. Saji H, Watanabe A, Magata Y, et al. Evaluation of radioiodinated 5-iodo-3-(2(S)-azetidinylmethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. Ann Nucl Med. 2002;16:189–200
  118. Mitsis EM, Cosgrove KP, Staley JK, et al. [123I]5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptor availability in the aging human brain. Ann N Y Acad Sci. 2007;1097:168–170
  119. McGeer PL, Itagaki S, Akiyama H, et al. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 1988;24:57457-6
  120. Dawson VL, Dawson TM, Bartley DA, et al. Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13:2651–2661
  121. Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid Redox Signal. 2003;5:319–335
  122. Ihara Y, Chuda M, Kuroda S, et al. Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. J Neurol Sci. 1999;170:90–95
  123. Jenner P, Dexter DT, Sian J, et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease (The Royal Kings and Queens Parkinson's Disease Research Group). Ann Neurol. 1992;32(suppl):S82–S87
  124. Vitte J, Michel BF, Bongrand P, et al. Oxidative stress level in circulating neutrophils is linked to neurodegenerative diseases. J Clin Immunol. 2004;24:683–692
  125. Banati RB. Visualising microglial activation in vivo. Glia. 2002;40:206–217
  126. Banati RB, Egensperger R, Maassen A, et al. Mitochondria in activated microglia in vitro. J Neurocytol. 2004;33:535–541

PII: S0001-2998(08)00046-9

doi: 10.1053/j.semnuclmed.2008.03.001

Seminars in Nuclear Medicine
Volume 38, Issue 4 , Pages 274-286 , July 2008

Article Tools

* Image Usage & Resolution